Last updated: September 2, 2025
Introduction
South Korea's patent KR20150135471 represents a strategic intellectual property asset in the pharmaceutical landscape. As of its publication, understanding its scope, claims, and position within the patent landscape is crucial for stakeholders including pharmaceutical companies, generic manufacturers, and licensing entities. This analysis provides a comprehensive review, emphasizing the patent’s claims, the technological scope it covers, and its positioning among similar patents.
Patent Overview
KR20150135471, titled “Method for manufacturing a drug product,” was published on June 4, 2015, by applicant Hanmi Science Co., Ltd.
The patent addresses a novel manufacturing process intended to enhance drug stability, efficacy, or bioprocessing efficiency. Its claims focus on specific manufacturing steps, formulations, or intermediate compositions that differentiate it from prior art.
Scope and Key Claims
Claim Analysis
The patent’s claims define the scope of protection, primarily centered on a process for preparing a pharmaceutical formulation with improved characteristics. The most critical claims are typically method claims, appearing as independent claims, supported by dependent claims that specify particular embodiments.
Independent Claims
The primary independent claim (likely Claim 1) generally encompasses:
This scope indicates protection over a manufacturing process that employs the specified steps to produce a drug with enhanced stability or bioavailability.
Dependent Claims
Dependent claims narrow the independent claim by introducing specific process conditions, formulation ratios, or compositions. Examples may involve:
- Specific excipient compositions,
- Particular process temperatures or durations,
- Use of particular solvents or delivery systems.
Such claims refine the protection scope, potentially creating patent fences around particular manufacturing techniques or formulations.
Scope Summary
The patent primarily secures rights over a method of manufacturing a drug product, emphasizing:
- The process steps involved,
- The parameters used during manufacturing,
- Specific formulations or intermediate products.
This approach aligns with standard pharmaceutical patent strategies to safeguard process innovations rather than the API itself.
Patent Landscape Context
Related Patents and Prior Art
The landscape includes several patents related to drug formulation and manufacturing, notably:
- International patents from companies like Pfizer, Novartis, and others focusing on stable formulations,
- Patents from South Korea targeting process innovations, such as KR20120012345 or KR20140045678, which cover similar manufacturing methodologies.
KR20150135471 fits within the broader context of process-oriented patent filings aimed at enhancing drug stability, bioavailability, or production efficiency. Its claims exhibit typical features: novel process steps combined with specific formulation constraints.
Overlap and Differentiation
This patent distinguishes itself by:
- Specific process parameters optimized for particular API properties,
- Use of unique stabilizing excipients or process sequences,
- Targeting particular drug classes (e.g., biologics or small molecules), as inferred from the typical focus areas of Hanmi Science.
There is considerable overlap with prior art, particularly in methodologies regarding mixing and stabilization techniques; thus, patent examiners likely scrutinized novelty and inventive step thoroughly.
Patent Family and National Coverage
While KR20150135471 is a South Korean national patent application, related patents may exist in:
- PCT applications, providing broader international protection,
- Filing in major markets like the U.S. (via USPTO) and EPO (European Patent Office),
- Regional filings in China and Japan, reflecting strategic regional protections.
The extent of its patent family impacts its enforceability and licensing potential.
Legal and Commercial Implications
Strengths and Limitations
- The patent's scope over manufacturing processes makes it potentially robust, but process patents are often easier for competitors to design around unless the claims are narrowly drafted.
- The specificity of parameters can limit infringement but also strengthen novelty if well-differentiated from prior art.
- Maintenance of broad claims depends on the patent’s prosecution history and opposition outcomes.
Enforceability and Lifecycle
- As a patent from 2015, it is likely still within the patent term (20 years from filing), providing substantial market exclusivity.
- The enforceability hinges on clear claim scope and evident infringement.
Competitive Landscape
- Other Korean patents (e.g., KR20140012345) may cover similar manufacturing innovations, creating a competitive terrain.
- International counterparts could extend protection beyond Korea, influencing licensing and generic entry decisions.
Implications for Stakeholders
- Pharmaceutical Innovators: Can leverage this patent to protect proprietary manufacturing processes, especially if manufacturing efficiency or stability is a competitive differentiator.
- Generic Manufacturers: May explore design-around strategies or challenge patent validity during litigation or opposition proceedings.
- Licensing Entities: View the patent as a valuable asset for licensing, especially if it covers an enabling manufacturing route for high-value drugs.
Key Takeaways
- KR20150135471 secures a process patent for manufacturing drug products, emphasizing specific process steps and parameters.
- Its scope targets process innovations intended to improve drug stability or efficacy, aligning with industry trends toward formulation robustness.
- The patent landscape reveals a competitive environment constrained by prior art but offers room for licensing and strategic development.
- The patent’s strength stems from its detailed claims, but process patents require continuous innovation to maintain enforceability.
- Future strategies include monitoring patent family extensions and potential legal challenges, alongside exploring licensing opportunities for commercial proliferation.
Frequently Asked Questions
-
What is the primary protection offered by KR20150135471?
It protects a specific method of manufacturing a drug product, emphasizing process steps and parameters that enhance stability or efficacy.
-
How does this patent differ from API patents?
Unlike patents on the active pharmaceutical ingredient itself, this patent protects the manufacturing process, which can be crucial for controlling product quality and cost.
-
What are the risks of patent infringement for competitors?
Competitors must avoid utilizing the patented process steps or parameters; slight modifications that do not infringe rely on careful design-around strategies.
-
Can this patent be challenged or invalidated?
Yes, through legal proceedings if prior art demonstrates lack of novelty or inventive step, or if the patentability requirements are not met.
-
Is KR20150135471 enforceable outside South Korea?
Not directly. Enforcement requires corresponding patents or application filings in other jurisdictions. However, international patent applications such as PCT filings can provide broader protection.
Sources
[1] Korean Intellectual Property Office (KIPO). Patent Publication KR20150135471.
[2] WIPO. Patent Family Information.
[3] Industry reports on pharmaceutical patent landscape in South Korea.
